228 results about "Phosphatidyl Cholines" patented technology

The invention belongs to the technical field of cosmetics, and particularly relates to whitening cream and a preparation method thereof. The whitening cream comprises the following preparation raw materials of nicotinamide, resveratrol, 3-o-ethyl ascorbic acid, a peony extract, diglucosyl gallic acid, a caviar extract, phosphatidylcholine, ceramide 3, p-hydroxyacetophenone, tocopheryl acetate, sodium hyaluronate, 7-10% of a humectant, an emollient, an emulsifying agent, a thickening agent, a neutralizer, essence and water. The whitening cream disclosed by the invention can take effect in multiple ways of melanin generation inducement, melanin generation process, melanin transfer, melanin digestion and discharge process and the like, and the purpose of quickly whitening skin and dispellingfreckles can be achieved.

The invention discloses a hollow lipid microfoam composition with fluorocarbon/nitrogen and preparing method, wherein the microfoam filming material is composed of phosphatide, protective and polymer; the phosphatide is selected from phosphatidyl Choline and phosphatidyl ethanolamine; the protective can be middle and macromolecular hydroxyethyl amidon; the polymer is selected from boluoshamu 188 or medically acceptable surface activator for vein injection; the lipid filming material covers the fluorocarbon liquid to form emulsion particle, which forms hollow lipid microball under high temperature instantaneously through gasifying the liquid fluorocarbon; the fluorocarbon/ nitrogen is guided to produce the lipid microball for ultrasonic imaging with effectively reinforcing time over 60 min. The invention has high yield rate and fast manufacturing speed, which improves the microball dispersity and microball density effectively.

The invention provides lipid-based dispersion comprising comprising, a) phosphatidyl choline; b) an anionic phospholipid; optionally c) up to 1% cholesterol by weight of total lipids; and optionally d) a therapeutic agent; wherein the mean particle size measured by dynamic light scattering is less than 100 nm. The invention also provides pharmaceutical compositions comprising such a dispersion as well as methods of producing a therapeutic effect in a mammal comprising administering an effective amount of such a dispersion.

The invention discloses a method for preparing lysophosphatidyl choline by enzymatic alcoholysis, which comprises: adding phosphatidylcholine into low-carbon alcohol solution, uniformly stirring and mixing at a certain temperature, adding lipase, and allowing the lipase to catalyze the alcoholysis of phosphatidylcholine with constant-temperature stirring to obtain the lysophosphatidyl choline. The method has the advantages that: (1) the solubility of phosphatidylcholine, lysophosphatidyl choline serving as the product, and aliphatic ester, glycerophosphorylcholine and very small amount of fatty acid, which serve as byproducts, in the reaction system is improved, and the conversion rate of the lysophosphatidyl choline is high; (2) the aliphatic ester, a small amount of glycerophosphate and a very small amount of fatty acid are generated in an alcoholysis reaction process, but the pH value of the system is not changed, and the influence of the solvent on the activity of the lipase is relieved and the catalytic reaction activity of the lipase is high; (3) the properties of the fatty acid, the aliphatic ester and glycerophosphorylcholine, which are products of side reactions, are very different from those of the lysophosphatidyl choline, so the lysophosphatidyl choline product can be separated and purified very easily; and (4) the alcohol, which is the product of the reaction, can be removed easily.

The invention discloses a breviscapinum long-circulating nanoliposome and its preparation method, wherein the constituents include breviscapine, phosphatide, polyethylene glycol derived phosphatide (PEG2000-DSPE) and cholestrin by a molar ratio of 55:25-55:3-7:2.2-18.3, the dose type of the medicinal preparation includes injections, freeze-dried powder injections and sprays. The phospholipids can be soya bean lecithin, yolk phosphatidy icholine, hydrogenated soya bean lecithin, hydrogenated yolk lecithin, di-palmityl phosphatidyl choline or DPOG.

The invention provides a polyurethane material with side chain possessing fluorophosphatidylcholine and its preparation method, which is prepared through alternating copolymerization of a soft segment composed of polyether dihydroxy alcohol and/or polycarbonate diatomic alcohol and a rigid chain segment formed by diisocyanate and chain expanding agent, characterized in that the copolymer comprises the following repetition structural elements, wherein the partial rigid chain segment side chain contains fluorine-containing phosphatidyl choline groups, whose weight average molecular weight is 30000-60000.

The invention belongs to the technical field of medicine; in order to solve the problem that no efficient and safe cartilage siRNA delivery system is provided for limiting application of RNAi in treating cartilage diseases, the invention provides a cartilage siRNA liposome delivery system and a preparation method of the delivery system. The delivery system consists of lipidosome, a lipidosome modifier and a small nucleic acid drug, wherein the lipidosome is phosphatidylcholine, cholesterol or Dlin-KC2-DMA; the lipidosome modifier is a polyethylene glycol lipid conjugate; and the small nucleic acid drug is Ihh siRNA. According to the invention, a liposome nano based cartilage RNA interference delivery system is modified, and the formed composite has positive charges, is safe and small in volume, and can be distributed in a full-lamellar cartilage tissue. Carrier experiments verify that siRNA can be delivered into cartilage cells to successful knock out corresponding genes inside the cartilage cells, therefore a bottleneck of gene knockout in the cartilage tissue is broken through; and the siRNA, as a target gene, can be used for treating PTOA (post-traumatic osteoarthritis).

The invention provides an emulsion composition containing lecithin, DHA, other fat-soluble substances and purified water. The content of the purified water in the emulsion composition is more than 70% by weight, the weight ratio of the lecithin to the DHA is 1: (0.005-1), the particle size of fat balls in the emulsion is less than 5 mu m, and the other fat-soluble substances comprise one or more of the following components: arachidonic acid, linolenic acid, alpha-linolenic acid, gamma-linolenic acid, linoleic acid, conjugated linoleic acid, conjugated linoleic acid glyceride, phosphatidylserine, polyene phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl glycerol, phytosterol, plant sterol ester, plant stanol ester and medium and long-chain fatty acid. The invention further provides a preparation method of the emulsion composition and application of the emulsion composition in the functional aspects of supplementing phospholipids and unsaturated fatty acids by oral administration, protecting heart and brain blood vessels, reducing blood lipids, reducing blood pressure, treating fatty liver and the like.

This invention relates to a highly efficient artificial low-density lipoprotein (LDL) carrier system for the targeted delivery therapeutic agents across the blood-brain barrier (BBB). In particular, this invention relates to artificial LDL particles comprised of three lipid elements: phosphatidyl choline, fatty-acyl-cholesterol esters, and at least one apolipoprotein. The present invention further relates to compositions, methods and kits comprising artificial LDL particles for targeting drugs to and across the BBB for the prevention and treatment of brain diseases.

The invention relates to a phosphatidyl choline freeze powder injection and relative preparation, wherein said formula is formed by phosphatidyl choline, solubilizer, support agent and other additive components; the phosphatidyl choline content is 10-60%; the solubilizer can colalin, glycocholic acid, cholaic acid, deoxycholic acid, anthrodsoxycholic acid, or taurodeoxycholic acid and relative salt, loxapine and tween; the support agent can be freeze protector. The invention has high stability, which can be stored for 1 year at normal temperature, without allergic and excitation.

The invention provides a cefmetazole sodium proliposome preparation which comprises the following components by weight part: 1 part of cefmetazole sodium, 3-15 parts of liposome carrier and 2-10 parts of proppant, wherein the liposome carrier comprises polyene phosphatidyl choline, cholesterol and oleinic acid according to a weight ratio of (4-20):(1-5):1. The cefmetazole sodium proliposome preparation has good preparation stability and cannot crack because of dewatering, fusion, ice crystal generation, and the like in a freeze-drying process; and after hydrated re-dissolution, the cefmetazole sodium proliposome preparation still can maintain good entrapment rate.

Pharmaceutical compositions comprising an aptamer and an amino acid ester or amide or an aptamer; a divalent metal cation; and a carboxylic acid, a phospholipid, a phosphatidyl choline, or a sphingomyelin. Methods of treating or preventing a condition in an animal comprising administering to the animal the pharmaceutical compositions.

The invention belongs to the technical field of genetic engineering of enzymes, and particularly relates to a method for obtaining phosphatidase B mutants with improved enzyme activity through a PCR (sequential error-prone) technology in vitro directed evolution, using the phosphatidase B mutants to prepare glycerophosphatidylcholine and performing oil degumming. The phosphatidase B mutant PLBM is obtained; the enzyme activity is improved by 25 percent through being compared with that of wild phosphatidase B.

An improved ionic liquid membrane and its preparation for separation of olefins/paraffins is described. The membrane comprises an ionic liquid with a metal salt. The ionic liquid includes a choline salt, selected from choline, chloride/hydroxide/bitratrate, phosphatidylcholine and is a deep eutectic liquid. The metal salt selected from silver, copper, gold, mercury, cadmium, zinc with choloride, nitrate, tetrafluoroborate, triflate, cyanide, thiocyanide, tetraphenylborate as anion. The ionic liquid is eutectic or a so-called deep eutectic liquid. The experimental examples use choline chloride, urea and silver nitrate/chloride and are tested for methane/ethene separation.

The invention provides a composite phospholipid transfersome which promotes propranolol percutaneous absorption, and a preparation method thereof. According to the invention, two phospholipid materials with different phase-change temperatures, which are dipalmitoyl phosphatidyl choline and soybean lecithin, are adopted as a composite phospholipid material. Compared with a transfersome with a single phospholipid material in prior art, the propranolol composite phospholipid transfersome prepared with the phospholipid material provided by the invention has substantially improved encapsulation efficiency, reduced leakage, improved stability in rat plasma, and substantially improved bioavailability after percutaneous administration. The propranolol composite phospholipid transfersome provided by the invention is especially suitable to be used for treating infantile hemangioma. With the transfersome, propranolol percutaneous administration can be realized, and propranolol can directly act upon a hemangioma affected part. The treatment effect is improved, toxic and side effects are reduced, and children medication compliance can be improved. Also, the invention provides a preparation method of the propranolol composite phospholipid transfersome.

The present disclosure concerns a cream-based composition and method which reduces fat deposits upon topical application to the skin. The active ingredients of the composition include the active ingredients deoxycholic acid and phosphatidyl choline which are mixed together with a cream composition. The active ingredients may be combined with any suitable pharmaceutical vehicle to provide the fat-reducing composition claimed herein. The composition is topically applied to a skin area over a period of days or months in order to reduce fat deposits that have collected beneath the dermis.

The present disclosure provides a multi-metabolite platform using one or more metabolite selected from a group consisting of tryptophan, homoserine, fatty acid (16:1), fatty acid (18:0), fatty acid (18:1), fatty acid (18:2), fatty acid (22:6), phosphatidylcholine (PC) (34:2), PC (34:3), lysophosphatidylcholine (lysoPC) (16:0), lysoPC (18:0), lysoPC (20:3), lysoPC (20:4), lysoPC (22:6), monoglyceride (18:1/0:0/0:0) and sphingomyelin (d18:2/16:0) as a biomarker, which can diagnose acute coronary syndrome as well as the symptoms occurring prior to the onset of the disease simply and accurately through in-vivo level analysis.

The invention relates to a thermosensitive liposome, which contains at least one phosphatidylcholine, at least one lysophospholipid, and at least one unsaturated phospholipid. The phase temperature of the liposome is 39.0DEG C-45.0DEG C. The liposome further contains a material having a long circulating characteristic and a fat-soluble active agent. Specifically, the phosphatidylcholine, the lysophospholipid, the unsaturated phospholipid, and the material having a long cycle characteristic are in a weight ratio of 69-94:1-6:1-10:4-15. And all the phospholipids and the fat-soluble active agent are in a weight ratio of 30-120:1-10. The invention also relates to a pharmaceutical composition containing the thermosensitive liposome. The invention additionally relates to application of the thermosensitive liposome and the pharmaceutical composition in preparing drugs treating tumors.